Andexxa phase IV trial stopped early after achieving pre-specified criteria on haemostatic efficacy versus usual care – AstraZenca
ANNEXA-I, a post-marketing Phase IV trial to assess the efficacy and safety of Andexxa (andexanet alfa) from AstraZeneca in patients on oral FXa-inhibitor treatment including apixaban and rivaroxaban… read more.
